ArticleBlood2019
Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications.
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Fibrin formation and lysis in hyperglycaemia - molecular and cellular drivers.Current opinion in hematology · 2026Review
- Adhirons are efficient tools to guide antiviral ligand discovery.Communications biology · 2025Article
- Transfusion biomaterials for hemostasis.Journal of thrombosis and haemostasis : JTH · 2025Review
- Exploiting the Molecular Properties of Fibrinogen to Control Bleeding Following Vascular Injury.International journal of molecular sciences · 2025Review
- Use of Affimer technology for inhibition of α2-antiplasmin and enhancement of fibrinolysis.Blood advances · 2025Article
- Affimer reagents as tool molecules to modulate platelet GPVI-ligand interactions and specifically bind GPVI dimer.Blood advances · 2024Article
- Biological Applications of Synthetic Binders Isolated from a Conceptually New Adhiron Library.Biomolecules · 2023Article
- ENGINEERED INTRAVENOUS THERAPIES FOR TRAUMA.Current opinion in biomedical engineering · 2023Article
- Hydrophobic aerogel-modified hemostatic gauze with thermal management performance.Bioactive materials · 2023Article
- Fbg αC 389-402 Enhances Factor XIII Cross-Linking in the Fibrinogen αC Region Via Electrostatic and Hydrophobic Interactions.Biochemistry · 2023Article
- Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics.International journal of molecular sciences · 2021Review
- Host-Pathogen Adhesion as the Basis of Innovative Diagnostics for Emerging Pathogens.Diagnostics (Basel, Switzerland) · 2021Review
- Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.International journal of molecular sciences · 2021Review
- Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk.Haematologica · 2021Article
- POLArIS, a versatile probe for molecular orientation, revealed actin filaments associated with microtubule asters in early embryos.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- A unique group of scabies mite pseudoproteases promotes cutaneous blood coagulation and delays plasmin-induced fibrinolysis.PLoS neglected tropical diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
Abstract
Bleeding complications secondary to surgery, trauma, or coagulation disorders are important causes of morbidity and mortality. Although fibrin sealants are considered to minimize blood loss, this is not widely adopted because of its high cost and/or risk for infection. We present a novel methodology employing nonantibody fibrinogen-binding proteins, termed Affimers, to stabilize fibrin networks with the potential to control excessive bleeding. Two fibrinogen-specific Affimer proteins, F5 and G2, were identified and characterized for their effects on clot structure/fibrinolysis, using turbidimetric and permeation analyses and confocal and electron microscopy. Binding studies and molecular modeling identified interaction sites, whereas plasmin generation assays determined effects on plasminogen activation. In human plasma, F5 and G2 prolonged clot lysis time from 9.8 ± 1.1 minutes in the absence of Affimers to 172.6 ± 7.4 and more than 180 minutes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.